Palm Beach Neurological Center is participating in a clinical trial to examine if an investigational drug may help slow or stop memory loss in people with early stages of Alzheimer’s disease. It is an “Investigational” drug, meaning it has not yet been approved by regulatory...
Middle aged individuals in their 40s and 50s who have biomarkers linked to inflammation in their blood may have more brain shrinkage years later than individuals without these biomarkers, according to a study published in an article published in an issue of the medical journal...
Description Palm Beach Neurological Center is participating in a clinical research study to evaluate an investigational drug called “Delphia” for patients suffering from Dementia with Lewy Bodies. An investigational drug is not yet approved for use by the public. Doctors perform these studies to make sure...
Description Palm Beach Neurological Center is participating in a global clinical research study to prevent or delay Alzheimer’s disease in cognitively healthy, older individuals that have been identified with one or two major genetic risk factors for the onset of Alzheimer’s disease. The Generation Study 2 is...
Description A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease. The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase. In the placebo-controlled phase, eligible participants will...
Description The MissionAD study program is a clinical research program testing an investigational drug for the early stages of Alzheimer’s disease. (“Investigational” means the drug isn’t yet approved for use by the public.) Doctors are studying this investigational drug to make sure it is safe and...
The nosology and treatment options for cognitive impairment in Parkinson disease (PD) remains perhaps the greatest unmet clinical need. [1] The reported frequency of mild cognitive impairment (MCI) in newly diagnosed PD has ranged from 22% to 43%. [2,3] A proportion of those with PD-MCI...
Originally posted on www.neurology.org Methods: We assessed a cohort of older adults (n = 175, mean age 73 years, 57% female, 65% white) with repeated measures of gait speed over 14 years, MRI for gray matter volume (GMV) at year 10 or 11, and adjudicated cognitive...
Originally posted on www.neurology.org Dementia with Lewy bodies (DLB) is currently diagnosed clinically by identifying dementia in combination with a number of hallmark features: REM sleep behavior disorder (RBD), prominent visual hallucinations, parkinsonism, and marked fluctuations of cognition and alertness.1 DLB is often underdiagnosed, suggesting a...
Description The "IDEAS" Study stands for Imaging Dementia-Evidence for Amyloid Scanning. The purpose of this study is to improve the way doctors are able to take images of the brain and better treat dementia and memory-related conditions. Over 8,000 medicare patients are expected to be in the study,...